Patents by Inventor John Chabala

John Chabala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinazolinone KSP inhibitors
    Patent number: 7671200
    Abstract: Quinazolinones of formulae (a, b, c and d) are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
    Type: Grant
    Filed: June 28, 2007
    Date of Patent: March 2, 2010
    Assignee: Cytokinetics, Inc.
    Inventors: Jeffrey Finer, Gustave Bergnes, Bainian Feng, Whitney Smith, John Chabala
  • Methods and compositions utilizing quinazolinones
    Publication number: 20070254902
    Abstract: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
    Type: Application
    Filed: April 17, 2007
    Publication date: November 1, 2007
    Inventors: Jeffrey Finer, Gustav Bergnes, Whitney Smith, John Chabala, Bainian Feng
  • Phenothiazine kinesin inhibitors
    Publication number: 20060014736
    Abstract: Phenothiazine derivatives of formula (I) are disclosed. The compounds are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.
    Type: Application
    Filed: September 16, 2005
    Publication date: January 19, 2006
    Applicant: Cytokinetics, Inc.
    Inventors: Jeffrey Finer, John Chabala
  • Compounds for enzyme inhibition
    Publication number: 20050245435
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: April 14, 2005
    Publication date: November 3, 2005
    Applicant: Proteolix, Inc.
    Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser, John Schneekloth, John Chabala
  • Methods and compositions utilizing quinazolinones
    Publication number: 20050187232
    Abstract: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
    Type: Application
    Filed: March 21, 2005
    Publication date: August 25, 2005
    Inventors: Jeffrey Finer, Gustave Bergnes, Whitney Smith, John Chabala, Bainian Feng
  • Immunologic glycolipid adjuvants
    Patent number: 4189471
    Abstract: Glycolipid compounds of the formulae ##STR1## are useful immunologic adjuvants in vaccines.
    Type: Grant
    Filed: July 11, 1978
    Date of Patent: February 19, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Mitree M. Ponpipom, John Chabala, Tsung-Ying Shen